Plexus Corp. 10-Q Summary: Quarter Ended March 31, 2003
Business Context and Reporting Period
This Form 10-Q covers the three and six months ended March 31, 2003. Plexus Corp. provides product realization services, including design, manufacturing, and testing, to original equipment manufacturers (OEMs) in the networking, medical, industrial, computer, and transportation sectors. The company operates 24 facilities across North America, Europe, and Asia. The reporting period was significantly impacted by weak end-market demand in technology sectors and major restructuring initiatives.
Key Financial Metrics
| Metric (in thousands) | 3 Months Ended Mar 31, 2003 | 6 Months Ended Mar 31, 2003 |
|---|---|---|
| Net Sales | $190,773 | $396,152 |
| Gross Profit | $9,623 | $25,163 |
| Gross Margin | 5.0% | 6.4% |
| Operating Loss | $(7,192) | $(40,247) |
| Net Loss | $(5,044) | $(49,358) |
| Net Loss Per Share (Diluted) | $(0.12) | $(1.17) |
| Cash and Cash Equivalents | $79,503 | $79,503 |
| Short-term Investments | $33,311 | $33,311 |
| Operating Cash Flow (6 Months) | $11,696 |
Debt and Liquidity: The company terminated its Credit Facility on December 26, 2002, due to anticipated covenant noncompliance. As of March 31, 2003, no amounts were outstanding under this facility. The company utilizes an asset securitization facility with $22.6 million available, of which $15.0 million was utilized. Total liabilities to equity ratio was approximately 0.4 to 1.
Material Changes vs. Prior Period
- Revenue Decline: Net sales decreased 17% year-over-year for the quarter and 8% for the six-month period, driven by reduced demand in networking, computing, and industrial markets.
- Margin Compression: Gross margin dropped to 5.0% for the quarter (from 8.9% in 2002) due to low capacity utilization, lower pricing, and inefficiencies from program transfers.
- Restructuring Charges: The company recorded $31.8 million in restructuring charges for the six months ended March 31, 2003 (all in Q1). This includes the closure of the San Diego facility, workforce reductions, and asset write-downs. This compares to $7.5 million in the prior year period.
- Goodwill Impairment: A cumulative effect of a change in accounting for goodwill (SFAS No. 142) resulted in a $23.5 million net-of-tax charge ($28.2 million pre-tax) for transitional impairment at North American locations. An additional $5.6 million goodwill impairment was recorded related to the San Diego closure.
- Customer Concentration: Siemens Medical Systems became the largest customer, accounting for 15% of sales in the quarter, whereas no single customer exceeded 10% in the prior year.
Guidance, Outlook, and Risks
Outlook: Management expects third-quarter sales to range between $190 million and $200 million, though results depend on actual order levels. The company anticipates realizing cost savings from restructuring initiatives in the fourth quarter of fiscal 2003.
Subsequent Restructuring: In April 2003, the company announced additional restructuring activities, including the closure of a Kentucky facility and further workforce reductions. These actions are expected to incur approximately $12 million in additional charges in the second half of fiscal 2003, with estimated annualized savings of $6 million to $8 million.
Risks and Contingencies:
- Customer Dependency: High concentration of sales among the top 10 customers (54% of sales) creates vulnerability to order cancellations or delays.
- Financing: The company is assessing the replacement of its terminated Credit Facility. While current liquidity is sufficient, future access to capital is not guaranteed.
- ERP Implementation: Significant unamortized costs ($27.6 million) related to a new enterprise resource planning system pose a risk of impairment if the project is curtailed.
- Global Risks: Operations in China and Malaysia expose the company to foreign exchange fluctuations, political instability, and potential disruptions from the SARS epidemic.
Investor Verification Checklist
- Verify the status and terms of any new credit facility replacement for the terminated Credit Facility.
- Monitor the execution of the $12 million subsequent restructuring plan and the realization of projected cost savings.
- Assess the impact of the San Diego facility closure on customer retention and program transitions.
- Review the progress and potential impairment risks associated with the $27.6 million in capitalized ERP costs.
- Track sales trends in the medical sector, which offset declines in other industries, to gauge diversification success.